Allovir Inc
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OFATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Vikas Sinha with full power of substitution and resubstitution and full power to act as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Vikas Sinha | Chief Executive Officer, President, Chief Financial Officer and Director(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) | March 7, 2025 |
| Vikas Sinha | ||
| /s/ David Hallal | Executive Director | March 7, 2025 |
| David Hallal | ||
| /s/ Jeffrey Bornstein | Director | March 7, 2025 |
| Jeffrey Bornstein | ||
| /s/ Malcolm Brenner, MD, PhD | Director | March 7, 2025 |
| Malcolm Brenner, MD, PhD | ||
| /s/ Derek Adams, PhD | Director | March 7, 2025 |
| Derek Adams, PhD | ||
| /s/ Morana Jovan-Embiricos, PhD | Director | March 7, 2025 |
| Morana Jovan-Embiricos, PhD | ||
| /s/ Juan F. Vera, MD | Director | March 7, 2025 |
| Juan F. Vera, MD | ||
| /s/ Shawn Tomasello | Director | March 7, 2025 |
| Shawn Tomasello | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023: | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.